Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1
暂无分享,去创建一个
S. Oka | H. Gatanaga | M. Takiguchi | T. Chikata | N. Kuse | T. Akahoshi | H. Murakoshi | Yu Zhang
[1] H. Schuitemaker,et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption , 2020, Nature Medicine.
[2] Gaurav D. Gaiha,et al. CD8+ T cells in HIV control, cure and prevention , 2020, Nature Reviews Immunology.
[3] S. Mallal,et al. CD8 T cells targeting adapted epitopes in chronic HIV infection promote dendritic cell maturation and CD4 T cell trans-infection , 2019, PLoS pathogens.
[4] V. Appay,et al. Priming of HIV-1-specific CD8+ T cells with strong functional properties from naïve T cells , 2019, EBioMedicine.
[5] S. Oka,et al. Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens , 2019, Journal of Virology.
[6] S. Oka,et al. Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication , 2018, Journal of Virology.
[7] S. Rowland-Jones,et al. Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control , 2018, EBioMedicine.
[8] S. Oka,et al. CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication , 2018, Retrovirology.
[9] R. Siliciano,et al. Targeting the Latent Reservoir for HIV‐1 , 2018, Immunity.
[10] M. Carrington,et al. HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E , 2017, Journal of Virology.
[11] S. Oka,et al. Control of HIV-1 by an HLA-B*52: 01-C*12 02 Protective Haplotype , 2017, The Journal of infectious diseases.
[12] Jerome H. Kim,et al. Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection , 2017, Science Translational Medicine.
[13] S. Oka,et al. Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses , 2016, Journal of Virology.
[14] Jeffrey M. Gerold,et al. Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys , 2016, Nature.
[15] C. Schönbach,et al. Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation. , 2016, Cell reports.
[16] Charles E. DeZiel,et al. Impact of Pre-adapted HIV Transmission , 2016, Nature Medicine.
[17] R. Siliciano,et al. HIV-specific CD8⁺ T cells and HIV eradication. , 2016, The Journal of clinical investigation.
[18] S. Oka,et al. Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes , 2015, Journal of Virology.
[19] P. Goulder,et al. Impact of HLA-B*35 subtype differences on HIV disease outcome in Mexico , 2014, AIDS.
[20] S. Deeks,et al. Immunologic strategies for HIV-1 remission and eradication , 2014, Science.
[21] V. Veloso,et al. Association of the HLA-B*52 allele with non-progression to AIDS in Brazilian HIV-1-infected individuals , 2014, Genes and Immunity.
[22] M. John,et al. Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population , 2014, Journal of Virology.
[23] R. Siliciano,et al. CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants , 2013, Retrovirology.
[24] M. John,et al. Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity , 2012, Journal of Virology.
[25] B. Walker,et al. HIV and HLA class I: an evolving relationship. , 2012, Immunity.
[26] M. Carrington,et al. HLA Class I-Mediated Control of HIV-1 in the Japanese Population, in Which the Protective HLA-B*57 and HLA-B*27 Alleles Are Absent , 2012, Journal of Virology.
[27] S. Oka,et al. Selection and Accumulation of an HIV-1 Escape Mutant by Three Types of HIV-1-Specific Cytotoxic T Lymphocytes Recognizing Wild-Type and/or Escape Mutant Epitopes , 2011, Journal of Virology.
[28] Jack T Stapleton,et al. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.
[29] David Heckerman,et al. Adaptation of HIV-1 to human leukocyte antigen class I , 2009, Nature.
[30] V. Appay,et al. CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.
[31] S. Oka,et al. Different Abilities of Escape Mutant-Specific Cytotoxic T Cells To Suppress Replication of Escape Mutant and Wild-Type Human Immunodeficiency Virus Type 1 in New Hosts , 2007, Journal of Virology.
[32] Jacques Fellay,et al. A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.
[33] Galit Alter,et al. De Novo Generation of Escape Variant-Specific CD8+ T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection , 2005, Journal of Virology.
[34] H. Inoko,et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR–SSOP–Luminex method in the Japanese population , 2005, Immunogenetics.
[35] Philip J. R. Goulder,et al. HIV-1 Viral Escape in Infancy Followed by Emergence of a Variant-Specific CTL Response1 , 2005, The Journal of Immunology.
[36] Bette Korber,et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA , 2004, Nature.
[37] Philip J. R. Goulder,et al. HIV and SIV CTL escape: implications for vaccine design , 2004, Nature Reviews Immunology.
[38] Todd M. Allen,et al. HIV evolution: CTL escape mutation and reversion after transmission , 2004, Nature Medicine.
[39] Stephen J O'Brien,et al. The influence of HLA genotype on AIDS. , 2003, Annual review of medicine.
[40] James Theiler,et al. Advantage of rare HLA supertype in HIV disease progression , 2003, Nature Medicine.
[41] H. Akari,et al. Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Cytolytic Activity and Cytokine Production , 2002, Journal of Virology.
[42] M. Carrington,et al. HLA and AIDS: a cautionary tale. , 2001, Trends in molecular medicine.
[43] H. Inoko,et al. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. , 2000, Tissue antigens.
[44] F. Marincola,et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[45] E. Karita,et al. HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. , 1999, AIDS.
[46] J. Goedert,et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. , 1999, Science.
[47] M A Nowak,et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.
[48] Philip J. R. Goulder,et al. Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.
[49] J. Goedert,et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection , 1996, Nature Medicine.
[50] C. Schönbach,et al. Fine tuning of peptide binding to HLA-B*3501 molecules by nonanchor residues. , 1995, Journal of immunology.
[51] V. Gnau,et al. Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behćet's disease. , 1995, International immunology.
[52] G. Shaw,et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.
[53] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[54] S Ferrone,et al. HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules. , 1994, International immunology.
[55] S. Ferrone,et al. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. , 1992, Journal of immunology.